Creative Medical Technology Holdings Inc reports results for the quarter ended March 31 - Earnings Summary
09/05/2025 22:46
Creative Medical Technology Holdings Inc CELZ.OQ reported a quarterly adjusted loss of 83 cents per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -73 cents. The lone analyst forecast for the quarter was for a loss of 52 cents per share. Revenue was $3.00 thousand; analysts expected zero. Creative Medical Technology Holdings Inc's reported EPS for the quarter was a loss of 83 cents. The company reported a quarterly loss of $1.64 million. Creative Medical Technology Holdings Inc shares had fallen by 3.7% this quarter and lost 9.5% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 18.8% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Creative Medical Technology Holdings Inc is $26.00 This summary was machine generated from LSEG data May 9 at 09:46 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.52 | -0.83 | Missed |
| Dec. 31 2024 | -0.63 | -1.12 | Missed |
| Sep. 30 2024 | -0.85 | -0.75 | Beat |
| Jun. 30 2024 | -0.84 | -1.11 | Missed |
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Buys 4 Million Biodefense Shares For $200,000 Cash And 1 Million Shares On Sept 24
Brief: Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 11:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM